key: cord-1049806-f507uesq
authors: Pullen, Matthew F; Skipper, Caleb; Hullsiek, Kathy H; Bangdiwala, Ananta S; Pastick, Katelyn A; Okafor, Elizabeth C; Lofgren, Sarah M; Rajasingham, Radha; Engen, Nicole; Galdys, Alison; Williams, Darlisha; Abassi, Mahsa; Boulware, David R
title: Symptoms of COVID-19 Outpatients in the United States
date: 2020-06-30
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofaa271
sha: fa5187d5537874ebae32555c7667626da7d26de8
doc_id: 1049806
cord_uid: f507uesq

BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due to insufficient diagnostic testing in the United States, there is a need for clinical decision-making algorithms to guide testing prioritization. METHODS: We recruited participants nationwide for a randomized clinical trial. We categorized participants into three groups: 1) those with confirmed SARS-CoV-2 infection, 2) those with probable SARS-CoV-2 infection (pending test or not tested but with a confirmed COVID-19 contact), and 3) those with possible SARS-CoV-2 infection (pending test or not tested and with a contact for whom testing was pending or not performed). We compared the frequency of self-reported symptoms in each group and categorized those reporting symptoms in early infection (0 – 2 days), mid-infection (3 – 5 days), and late infection (>5 days). RESULTS: Among 1,252 symptomatic persons screened, 316 had confirmed, 393 had probable, and 543 had possible SARS-CoV-2 infection. In early infection, those with confirmed and probable SARS-CoV-2 infection shared similar symptom profiles, with fever most likely in confirmed cases (p = 0.002). Confirmed cases did not show any statistically significant differences compared to unconfirmed cases in symptom frequency at any time points. The most commonly reported symptoms in those with confirmed infection were cough (82%), fever (67%), fatigue (62%), and headache (60%), with only 52% reporting both fever and cough. CONCLUSION: Symptomatic persons with probable SARS-CoV-2 infection present similarly to those with confirmed SARS-CoV-2 infection. There was no pattern of symptom frequency over time.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the current global COVID-19 pandemic. Similar to its predecessor, SARS-CoV-1, this novel coronavirus can cause severe lower respiratory tract infection, often complicated by acute respiratory distress syndrome (ARDS). SARS-CoV-2, however, can also present with a wider variability in clinical syndromes and severity. Guan et al. documented that cough (67%), fever (44%), and fatigue (38%) were the most common symptoms in 1,099 patients admitted to hospitals throughout mainland China [1] .

Another study out of China on 1,012 non-critically ill patients noted fever (75%) and cough (52%) as the predominant symptoms, but also reported a higher rate of diarrhea (15%) compared to the predominant symptoms presented in a February 2020 Joint WHO-China report of 55924 laboratory-confirmed cases within China [2, 3] . Shortness of breath and cough (88%) were highly prevalent symptoms in 24 intensive care unit (ICU) patients in Washington, USA, while rhinorrhea was present in 17% of these patients [4] . In a recent Italian study of 202 confirmed infected patients, 64% reported alteration of the sense of smell or taste [5] [6] [7] [8] . A recent publication by the CDC COVID-19 Response Team examined 9282 healthcare personnel with confirmed SARS-CoV-2 infection and found that among those with complete data, 92% reported at least one symptom. Of those with symptoms, the most common were muscle aches ( 66%) and headache (65%), with absences of smell or taste grouped as "other symptom" in 750 (16%) of cases examined [9] . The full spectrum of the signs and symptoms of SARS-CoV-2 infection is still being elucidated.

Accurate identification of COVID-19 disease is critical in order for proper containment.

Currently, the CDC recommends either a testing-based or a symptom-based strategy when determining whether to institute transmission precautions in persons with confirmed or suspected SARS-CoV-2 infection, with similar strategies used to determine when to remove Here, we present the most common SARS-CoV-2 symptoms among symptomatic outpatients. Recruitment began on March 17, 2020, and these data presented are through April 20, 2020.

The parent trial is still actively recruiting participants.

The parent trial includes two distinct cohorts: 1) asymptomatic household contacts of a COVID-19 case or healthcare workers who have had a high-risk exposure event (post-exposure prophylaxis), and 2) symptomatic, non-hospitalized, household contacts of a COVID-19 case or healthcare workers who have had a high-risk exposure event (pre-emptive therapy to reduce progression to severe infection). The screening survey allows participants to indicate whether or not they are experiencing cough, fever, shortness of breath, headache, diarrhea, rhinorrhea, sore throat, fatigue, muscle aches, sinus congestion, or lack of smell, with persons reporting (Table 1) .

Thus, when viewed without the context of symptom duration, it is difficult to separate probable and possible infections from one another. It may also suggest that those with confirmed infection had more severe (or multiple) symptoms leading them to seek care and receive testing.

To further explore the question of symptom temporality in SARS-CoV-2 infection, we examined reported rates of symptoms in those participants with confirmed infection who completed the screening survey during early infection (n = 77), mid-infection (n = 84) and late infection (n = 155) time points ( Table 2) . There was a borderline significant difference in the prevalence of fatigue across the three time points (p=0.011). There was no significant difference A c c e p t e d M a n u s c r i p t in the prevalence of the remaining symptoms included in our screening survey across these time points.

The median duration of symptoms at the time of screening was slightly longer in the confirmed group at 5 days (IQR 3 to 11), compared to 2 days (IQR 1 to 5) for probable infection and 3 days [IQR 1 to 7] for possible infection. In early infection, those with confirmed infection were more likely than those with unconfirmed infection to report fever, headache, fatigue, myalgia, and diarrhea (all p<0.01). At later time points, there were fewer differences between these groups (Supplemental Tables 1 -3 ).

Using symptoms to guide diagnostic decision-making in suspect COVID-19 infection may be problematic, particularly when symptoms have been present for several days. Cough, fever, and dyspnea have been previously described as the three most common symptoms of SARS-CoV-2 infection, promoted in guidelines as potential screening symptoms when deciding to test or not test a patient [11] . The data presented here demonstrates some pitfalls in using these symptoms, without further context, to guide diagnostic decisions. In our cohort, those with confirmed infection had similar reported symptoms in early, mid, and late infection, without a clear evolution of symptoms over time. Those with confirmed and probable infection had similar symptom profiles when viewed at similar timepoints, with only fever consistently more common in those with confirmed infection. In contrast, those with possible infection had a markedly different symptom profile in early infection compared to those with confirmed infection (Supplemental Table 1 ). As time from initial symptoms lengthens, the differences in the symptom profiles of confirmed and possible infection decreases (Supplemental Tables 2 and   3 ). Additionally, when viewed without temporal context, it became difficult to separate probable and possible infections ( Table 1) .

A c c e p t e d M a n u s c r i p t These data underscore the protean ways in which COVID-19 can manifest and the need for wide-scale testing. Prioritizing testing on those with compatible symptoms of short duration and a confirmed COVID-19 case contact would be highest yield based on a similar presentation to those with confirmed infection. Compatible symptoms in the absence of a confirmed case contact or of long duration, however, are less helpful when trying to determine the likelihood of

As with any study, there are limitations to our analysis. First, our data rely on patientreported symptoms without further clarification of the quality of those symptoms, such as diarrhea without specification of frequency. Second, we are exclusively studying outpatient disease, thus our findings are not generalizable to those with more severe disease who require hospitalization. Third, the lack of prompt (or available) testing nationwide significantly affected the composition of confirmed, probable, and possible cases. Often, the person screening for our study or their contact were simply unable to have testing performed. Among the 460 symptomatic healthcare workers, only 220 (48%) received test results. Further, ill contacts of study subjects were frequently unable to undergo testing. Additionally, it is possible that more stringent criteria were imposed on study subjects when seeking testing, thus biasing the symptoms reported within the confirmed case group.

In summary, when making diagnostic decisions for those with potential SARS-CoV-2 infection who present with mild disease, clinicians should consider that COVID-19 can present in a variety of ways. In areas where SARS-CoV-2 testing remains limited, clinicians can use the information we present to guide clinical decision-making and improve allocation of limited resources.

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital

Report of the WHO-China Joint Mission on Coronavirus Disease

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features Radiology

Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy

Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection

Characteristics of Health Care Personnel with COVID-19 -United States

Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Table 1 . Comparison of symptom frequency and percentage (presented as n (%)) and median duration of symptoms among those with confirmed SARS-CoV-2 infection, probable infection, or possible infection across all time points. Significance was measured using Fisher's exact test.

Confirmed Table 2 . Examination of symptom frequency and percentage (presented as n (%)) across early, mid, and late infection for those with confirmed positive SARS-CoV-2 infection as a means of assessing temporality of symptoms. Significance was measured using Fisher's exact test.